Ayman A. Daoud

Ayman Daoud practices at St. Luke's Hospital in Chesterfield, Missouri, part of St. Luke's Episcopal-Presbyterian Hospital.

Ayman Daoud's NPI, 1487013512, was assigned on February 17, 2016. Ayman Daoud holds Missouri license 2017008339.

Ayman Daoud's primary practice is St. Luke's Hospital, at 232 S Woods Mill Rd, Chesterfield, MO 63017 in St. Louis County. The practice phone is (314) 434-1500.

Ayman Daoud's primary practice is St. Luke's Hospital in Chesterfield, Missouri, part of St. Luke's Episcopal-Presbyterian Hospital. Ayman Daoud is also affiliated with Missouri Baptist Medical Center. The medical group on file is Orthwein Brain & Spine Center at St. Luke’s (Neurology and Neurosurgery). Dmand AI also links Ayman Daoud to 1 more hospital, 1 breast imaging center and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Ayman Daoud practices, 5 sites in all. Vendor and product names are available with a free account.

Neurology is Ayman Daoud's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Ayman Daoud is licensed in Missouri.

CMS data shows 1,220 Medicare services from Ayman Daoud across 17 procedure codes in 2024, for 583 Medicare patients. Medicare paid $99,734 for them.

CMS counts 583 Medicare patients who saw Ayman Daoud in 2024. The largest group is 75 to 84, with 238 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 6% are also on Medicaid. Their average risk score is 1.51, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Ayman Daoud's median patient age at 73, with 58% women.

In 2024, Ayman Daoud wrote 3,143 Medicare Part D claims for 569 patients. 95% of them were for generic drugs. CMS names the drug for 2,951 of them, across 47 drugs with 11 or more claims each, at $207,947 in total drug cost. In 2023, CMS named 2,672 claims across 47 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Ayman Daoud for performance year 2024, reported through an alternative payment model (APM). Ayman Daoud accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 788 general payments to Ayman Daoud from 58 drug and device companies from 2018 to 2025. Food and beverage make up the largest share, 99% of the total. Abbvie Inc. paid the most, $3,717.